Market Roundup 2019: Healthcare stocks in neck-to-neck competition Updated : December 27, 2019 06:18 AM IST In the last one year, Dr Lal Pathlabs (DLP) has risen 50 percent while its competitor Metropolis Healthcare surged 46 percent since April 15 this year. In terms of financial earnings and ratios over the recent years, DLP and Metropolis had a neck-to-neck tough fight. Last month, CLSA published a research report on DLP, retaining the ‘buy’ rating on the stock with the target price increased to Rs 1,800 from Rs 1,330 earlier. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.